RPL39P15

Across TCGA pan-cancer cohorts, RPL39P15 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of RPL39P15’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where RPL39P15 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL39P15 is over-expressed in tumor.

KIRP, KIRC, and LIHC are the cancer types where RPL39P15 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL39P15 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	II,III,IV	+0.580	.004	8	view →
KIRC	Female	II,III,IV	+0.760	<.001	7	view →
LIHC	Male	All	+0.450	<.001	4	view →
HNSC	All	All	+0.386	.007	4	view →
CHOL	All	All	+0.766	.017	3	view →
LUAD	All	All	+0.556	.001	3	view →
UCEC	All	IV	+0.975	.009	2	view →
THCA	Female	II,III,IV	+0.503	.002	2	view →
LUSC	All	All	+0.278	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

RPL39P15–KIRP

Open the KIRP breakdown →